These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 21927947)

  • 21. Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor α2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele.
    Iwami K; Shimato S; Ohno M; Okada H; Nakahara N; Sato Y; Yoshida J; Suzuki S; Nishikawa H; Shiku H; Natsume A; Wakabayashi T
    Cytotherapy; 2012 Jul; 14(6):733-42. PubMed ID: 22424217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I dendritic cell p53 peptide vaccine for head and neck cancer.
    Schuler PJ; Harasymczuk M; Visus C; Deleo A; Trivedi S; Lei Y; Argiris A; Gooding W; Butterfield LH; Whiteside TL; Ferris RL
    Clin Cancer Res; 2014 May; 20(9):2433-44. PubMed ID: 24583792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate.
    Salcedo M; Bercovici N; Taylor R; Vereecken P; Massicard S; Duriau D; Vernel-Pauillac F; Boyer A; Baron-Bodo V; Mallard E; Bartholeyns J; Goxe B; Latour N; Leroy S; Prigent D; Martiat P; Sales F; Laporte M; Bruyns C; Romet-Lemonne JL; Abastado JP; Lehmann F; Velu T
    Cancer Immunol Immunother; 2006 Jul; 55(7):819-29. PubMed ID: 16187085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial.
    Baek S; Kim CS; Kim SB; Kim YM; Kwon SW; Kim Y; Kim H; Lee H
    J Transl Med; 2011 Oct; 9():178. PubMed ID: 22013914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer.
    Chiappori AA; Williams CC; Gray JE; Tanvetyanon T; Haura EB; Creelan BC; Thapa R; Chen DT; Simon GR; Bepler G; Gabrilovich DI; Antonia SJ
    Cancer Immunol Immunother; 2019 Mar; 68(3):517-527. PubMed ID: 30591959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04.
    Carmichael MG; Benavides LC; Holmes JP; Gates JD; Mittendorf EA; Ponniah S; Peoples GE
    Cancer; 2010 Jan; 116(2):292-301. PubMed ID: 19924797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial.
    Leffers N; Lambeck AJ; Gooden MJ; Hoogeboom BN; Wolf R; Hamming IE; Hepkema BG; Willemse PH; Molmans BH; Hollema H; Drijfhout JW; Sluiter WJ; Valentijn AR; Fathers LM; Oostendorp J; van der Zee AG; Melief CJ; van der Burg SH; Daemen T; Nijman HW
    Int J Cancer; 2009 Nov; 125(9):2104-13. PubMed ID: 19621448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients.
    Palma M; Hansson L; Mulder TA; Adamson L; Näsman-Glaser B; Eriksson I; Heimersson K; Ryblom H; Mozaffari F; Svensson A; Gentilcore G; Österborg A; Mellstedt H
    Eur J Haematol; 2018 Jul; 101(1):68-77. PubMed ID: 29569742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial.
    Baek S; Kim YM; Kim SB; Kim CS; Kwon SW; Kim Y; Kim H; Lee H
    Cell Mol Immunol; 2015 Jan; 12(1):87-95. PubMed ID: 24976269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study.
    Svane IM; Pedersen AE; Johnsen HE; Nielsen D; Kamby C; Gaarsdal E; Nikolajsen K; Buus S; Claesson MH
    Cancer Immunol Immunother; 2004 Jul; 53(7):633-41. PubMed ID: 14985857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.
    Dijkgraaf EM; Santegoets SJ; Reyners AK; Goedemans R; Nijman HW; van Poelgeest MI; van Erkel AR; Smit VT; Daemen TA; van der Hoeven JJ; Melief CJ; Welters MJ; Kroep JR; van der Burg SH
    Oncotarget; 2015 Oct; 6(31):32228-43. PubMed ID: 26334096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602).
    Slingluff CL; Lee S; Zhao F; Chianese-Bullock KA; Olson WC; Butterfield LH; Whiteside TL; Leming PD; Kirkwood JM
    Clin Cancer Res; 2013 Aug; 19(15):4228-38. PubMed ID: 23653149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study-A Brief Research Report.
    Kjeldsen JW; Iversen TZ; Engell-Noerregaard L; Mellemgaard A; Andersen MH; Svane IM
    Front Immunol; 2018; 9():2145. PubMed ID: 30283461
    [No Abstract]   [Full Text] [Related]  

  • 34. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial.
    Trepiakas R; Berntsen A; Hadrup SR; Bjørn J; Geertsen PF; Straten PT; Andersen MH; Pedersen AE; Soleimani A; Lorentzen T; Johansen JS; Svane IM
    Cytotherapy; 2010 Oct; 12(6):721-34. PubMed ID: 20429791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
    Chianese-Bullock KA; Pressley J; Garbee C; Hibbitts S; Murphy C; Yamshchikov G; Petroni GR; Bissonette EA; Neese PY; Grosh WW; Merrill P; Fink R; Woodson EM; Wiernasz CJ; Patterson JW; Slingluff CL
    J Immunol; 2005 Mar; 174(5):3080-6. PubMed ID: 15728523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers.
    Svane IM; Pedersen AE; Johansen JS; Johnsen HE; Nielsen D; Kamby C; Ottesen S; Balslev E; Gaarsdal E; Nikolajsen K; Claesson MH
    Cancer Immunol Immunother; 2007 Sep; 56(9):1485-99. PubMed ID: 17285289
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response.
    Vreeland TJ; Litton JK; Qiao N; Philips AV; Alatrash G; Hale DF; Jackson DO; Peace KM; Greene JM; Berry JS; Clifton GT; Peoples GE; Mittendorf EA
    Clin Immunol; 2018 Jul; 192():6-13. PubMed ID: 29574039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma.
    Perales MA; Yuan J; Powel S; Gallardo HF; Rasalan TS; Gonzalez C; Manukian G; Wang J; Zhang Y; Chapman PB; Krown SE; Livingston PO; Ejadi S; Panageas KS; Engelhorn ME; Terzulli SL; Houghton AN; Wolchok JD
    Mol Ther; 2008 Dec; 16(12):2022-9. PubMed ID: 18797450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission.
    Chu CS; Boyer J; Schullery DS; Gimotty PA; Gamerman V; Bender J; Levine BL; Coukos G; Rubin SC; Morgan MA; Vonderheide RH; June CH
    Cancer Immunol Immunother; 2012 May; 61(5):629-41. PubMed ID: 22021066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I trial of Wilms' Tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy.
    Ohno S; Okuyama R; Aruga A; Sugiyama H; Yamamoto M
    Anticancer Res; 2012 Jun; 32(6):2263-9. PubMed ID: 22641661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.